Abivax SA (NASDAQ: ABVX) filed its Universal Registration Document with France's Autorité des Marchés Financiers and its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission on March 23, 2026, according to a company statement.

The Universal Registration Document includes the biotechnology company's 2025 annual financial report, management report with corporate governance details, and statutory auditor reports. The documents are available on the company's website and regulatory agency portals.

The clinical-stage biotechnology company focuses on developing therapeutics for chronic inflammatory diseases. Abivax's lead drug candidate, obefazimod (ABX464), is currently in Phase 3 clinical trials for treating moderately to severely active ulcerative colitis.

The company operates from locations in France and the United States. The regulatory filings represent standard annual reporting requirements for companies listed on both European and American exchanges.